CEL SCI Corp Net Income
| CVM Stock | USD 4.86 0.15 2.99% |
As of the 12th of February 2026, CEL SCI shows the Mean Deviation of 4.51, coefficient of variation of (2,083), and Risk Adjusted Performance of (0.03). CEL SCI Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CEL SCI Corp standard deviation and value at risk to decide if CEL SCI Corp is priced adequately, providing market reflects its regular price of 4.86 per share. Given that CEL SCI has information ratio of (0.06), we suggest you to validate CEL SCI Corp's prevailing market performance to make sure the company can sustain itself in the future.
CEL SCI Total Revenue |
|
Gross Profit | Market Capitalization | Revenue | Earnings Share (6.08) | Quarterly Revenue Growth (0.63) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -22.9 B | -21.7 B | |
| Net Loss | -29.1 M | -30.6 M | |
| Net Loss | -22.9 M | -24 M | |
| Net Loss | (5.64) | (5.92) | |
| Net Income Per E B T | 0.90 | 0.83 |
CEL | Net Income | Build AI portfolio with CEL Stock |
Evaluating CEL SCI's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into CEL SCI Corp's fundamental strength.
Latest CEL SCI's Net Income Growth Pattern
Below is the plot of the Net Income of CEL SCI Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CEL SCI Corp financial statement analysis. It represents the amount of money remaining after all of CEL SCI Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CEL SCI's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CEL SCI's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (25.41 B) | 10 Years Trend |
|
Net Income |
| Timeline |
CEL Net Income Regression Statistics
| Arithmetic Mean | (24,171,838) | |
| Coefficient Of Variation | (43.43) | |
| Mean Deviation | 8,379,815 | |
| Median | (25,411,055) | |
| Standard Deviation | 10,497,582 | |
| Sample Variance | 110.2T | |
| Range | 36.3M | |
| R-Value | (0.49) | |
| Mean Square Error | 88.9T | |
| R-Squared | 0.24 | |
| Significance | 0.04 | |
| Slope | (1,026,409) | |
| Total Sum of Squares | 1763.2T |
CEL Net Income History
Other Fundumenentals of CEL SCI Corp
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CEL SCI Net Income component correlations
CEL Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CEL SCI is extremely important. It helps to project a fair market value of CEL Stock properly, considering its historical fundamentals such as Net Income. Since CEL SCI's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CEL SCI's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CEL SCI's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could CEL diversify its offerings? Factors like these will boost the valuation of CEL SCI. Projected growth potential of CEL fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CEL SCI data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.08) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
Understanding CEL SCI Corp requires distinguishing between market price and book value, where the latter reflects CEL's accounting equity. The concept of intrinsic value - what CEL SCI's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CEL SCI's price substantially above or below its fundamental value.
It's important to distinguish between CEL SCI's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CEL SCI should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CEL SCI's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
CEL SCI 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CEL SCI's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CEL SCI.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in CEL SCI on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding CEL SCI Corp or generate 0.0% return on investment in CEL SCI over 90 days. CEL SCI is related to or competes with INmune Bio, Barinthus Biotherapeutics, Aligos Therapeutics, Kezar Life, OnKure Therapeutics, Tempest Therapeutics, and X4 Pharmaceuticals. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious ... More
CEL SCI Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CEL SCI's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CEL SCI Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 30.91 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 10.19 |
CEL SCI Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CEL SCI's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CEL SCI's standard deviation. In reality, there are many statistical measures that can use CEL SCI historical prices to predict the future CEL SCI's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.26) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CEL SCI's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CEL SCI February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 4.51 | |||
| Coefficient Of Variation | (2,083) | |||
| Standard Deviation | 6.1 | |||
| Variance | 37.2 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 30.91 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 10.19 | |||
| Skewness | 0.8528 | |||
| Kurtosis | 2.32 |
CEL SCI Corp Backtested Returns
CEL SCI Corp secures Sharpe Ratio (or Efficiency) of -0.0512, which signifies that the company had a -0.0512 % return per unit of return volatility over the last 3 months. CEL SCI Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CEL SCI's Mean Deviation of 4.51, coefficient of variation of (2,083), and Risk Adjusted Performance of (0.03) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.14, which signifies a somewhat significant risk relative to the market. CEL SCI returns are very sensitive to returns on the market. As the market goes up or down, CEL SCI is expected to follow. At this point, CEL SCI Corp has a negative expected return of -0.32%. Please make sure to confirm CEL SCI's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if CEL SCI Corp performance from the past will be repeated in the future.
Auto-correlation | 0.28 |
Poor predictability
CEL SCI Corp has poor predictability. Overlapping area represents the amount of predictability between CEL SCI time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CEL SCI Corp price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current CEL SCI price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.23 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CEL Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CEL SCI Corp reported net income of (25.41 Billion). This is 7545.75% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is significantly higher than that of the company.
CEL Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CEL SCI's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CEL SCI could also be used in its relative valuation, which is a method of valuing CEL SCI by comparing valuation metrics of similar companies.CEL SCI is currently under evaluation in net income category among its peers.
CEL SCI ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CEL SCI's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CEL SCI's managers, analysts, and investors.Environmental | Governance | Social |
CEL Fundamentals
| Return On Equity | -1.76 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 40.56 M | ||||
| Shares Outstanding | 8.41 M | ||||
| Shares Owned By Insiders | 8.16 % | ||||
| Shares Owned By Institutions | 11.05 % | ||||
| Number Of Shares Shorted | 522.42 K | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 11,797 X | ||||
| Gross Profit | (15.89 M) | ||||
| EBITDA | (20.88 M) | ||||
| Net Income | (25.41 B) | ||||
| Cash And Equivalents | 10.95 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 9.38 B | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 7.71 X | ||||
| Book Value Per Share | 1.99 X | ||||
| Cash Flow From Operations | (17.12 B) | ||||
| Short Ratio | 6.63 X | ||||
| Earnings Per Share | (6.08) X | ||||
| Target Price | 42.5 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 40.87 M | ||||
| Total Asset | 28.16 B | ||||
| Retained Earnings | (539.42 M) | ||||
| Working Capital | 6.47 M | ||||
| Current Asset | 5.89 M | ||||
| Current Liabilities | 4.01 M | ||||
| Net Asset | 28.16 B |
About CEL SCI Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CEL SCI Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CEL SCI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CEL SCI Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could CEL diversify its offerings? Factors like these will boost the valuation of CEL SCI. Projected growth potential of CEL fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CEL SCI data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.08) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
Understanding CEL SCI Corp requires distinguishing between market price and book value, where the latter reflects CEL's accounting equity. The concept of intrinsic value - what CEL SCI's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CEL SCI's price substantially above or below its fundamental value.
It's important to distinguish between CEL SCI's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CEL SCI should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CEL SCI's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.